The purpose of this clinical trial is to investigate whether IPC can improve aerobic capacity during exercise. The primary question it aims to answer is: Does IPC enhance the aerobic capacity of athletes? The researchers will compare IPC (220 mmHg pressure) with a placebo (20 mmHg pressure) to see if different interventions can enhance aerobic capacity and exercise performance.

Participants will:

• Undergo a randomized crossover controlled trial, visiting twice, with a one-week interval between each test.
• Conduct two assessments at the testing site each time, namely a pre-intervention assessment and a post-intervention assessment.
• Record their heart rate, blood pressure, weight, oxygen uptake, Taekwondo-specific performance, and other indicators.

Inclusion Criteria:

• adult male athletes aged 18 years or older;
• taekwondo athletes classified as national second-class or above (having placed in the top three provincial professional taekwondo championships or the top eight national professional taekwondo championships);
• consistent and unified training over the past three months;
• no prior ischemic preconditioning;
• competitive taekwondo athletes.

Exclusion Criteria:

• supplementation with creatine;
• acute or chronic illnesses, including anxiety, depression, cardiovascular diseases, and metabolic disorders;
• engaging in vigorous physical activity within 48 hours prior to the experiment;
• consuming alcohol or caffeine within 24 hours before the experiment.

The data presented in this study are currently unpublished. The corresponding author will provide the relevant research data upon reasonable request after the associated paper has been officially accepted.